Yaşar, Arzu
136  results:
Search for persons X
?
1

Kaposi sarcoma associated with rituximab-based cytotoxic th..:

Alkan, Ali ; Yaşar, Arzu ; Toprak, Serhat
Journal of Oncology Pharmacy Practice.  26 (2019)  1 - p. 220-223 , 2019
 
?
2

Vaccination in oncology practice and predictors:

Alkan, Ali ; Karcı, Ebru ; Yaşar, Arzu...
Supportive Care in Cancer.  25 (2017)  9 - p. 2677-2682 , 2017
 
?
3

Radiation-Induced Tumor Lysis Syndrome in Chronic Lymphocyt..:

Alkan, Ali ; Kütük, Tuğçe ; Karcı, Ebru...
Turkish Journal of Hematology.  33 (2016)  3 - p. 248-250 , 2016
 
?
4

Severe drug interactions and potentially inappropriate medi..:

Alkan, Ali ; Yaşar, Arzu ; Karcı, Ebru...
Supportive Care in Cancer.  25 (2016)  1 - p. 229-236 , 2016
 
?
 
?
9

Neutrophil–lymphocyte ratio as a prognostic factor for surv..:

Hizal, Mutlu ; Sendur, Mehmet AN ; Yasar, Hatime Arzu...
Journal of Oncology Pharmacy Practice.  26 (2020)  7 - p. 1583-1589 , 2020
 
?
10

Re: Combination of radiotherapy and immunotherapy? Do timin..:

Ürün, Yüksel ; Yaşar, H Arzu ; Turna, Hande...
Journal of Oncology Pharmacy Practice.  25 (2019)  8 - p. 2062-2063 , 2019
 
?
11

The relationship between prognostic nutritional index and t..:

Yasar, Hatime Arzu ; Bir Yucel, Kadriye ; Arslan, Cagatay...
Journal of Oncology Pharmacy Practice.  26 (2019)  5 - p. 1110-1116 , 2019
 
?
12

Risk factors for thrombosis risk in patients with cancer:

Turan, Dilara ; Yasar, Hatime Arzu ; Aksu, Ozge Bas...
Journal of Oncological Sciences.  4 (2018)  3 - p. 130-133 , 2018
 
?
14

Prognostic factors for survival in patients with metastatic..:

Urun, Yuksel ; Yasar, H Arzu ; Turna, Hande...
Journal of Oncology Pharmacy Practice.  25 (2018)  7 - p. 1658-1664 , 2018
 
1-15